Drugs

, Volume 62, Issue 12, pp 1755–1770 | Cite as

Combination of Low Molecular Weight Heparins with Antiplatelet Agents in Non-ST Elevation Acute Coronary Syndromes

An Update
Review Article

Abstract

This article reviews the use of low molecular weight heparin (LMWH) and antiplatelet agents in the treatment of unstable angina and non-ST segment elevation myocardial infarction (NSTEMI), which together account for 1 million hospitalisations annually in the US alone. Mortality and recurrent myocardial infarction (MI) in these conditions is currently approximately 8 to 16% at 1 month, and there is a need to optimise treatment further.

Since their introduction, LMWHs have been shown to be successful and well tolerated in the treatment of unstable angina and NSTEMI, but differences have been seen in their efficacy compared with the parent compound, unfractionated heparin (UFH). A meta-analysis of all LMWHs, grouped, versus UFH showed equivalent efficacy and safety. The LMWHs dalteparin sodium and nadroparin calcium have independently been shown to be as effective as UFH. However, enoxaparin sodium has been shown to have greater clinical efficacy than UFH in patients with unstable angina (UA)/NSTEMI.

One area of new research is patients with UA/NSTEMI who later undergo percutaneous coronary interventions (PCI), and early data suggest enoxaparin can be safely used as an anticoagulant instead of UFH in these patients. There is a wealth of data for glycoprotein (GP) IIb/IIIa receptor antagonists (abciximab, eptifibatide, lamifiban, and tirofiban), although some are conflicting. Recent meta-analyses suggest that some benefit is conferred by using these compounds, particularly in patients who undergo PCI.

Recent trials have focussed on combining GP IIb/IIIa antagonists with LMWH, and although data is still scant, the ACUTE (Anti-thrombotic Combination Using Tirofiban and Enoxaparin) and ACUTE II studies indicate the safety and potential clinical benefit of combining enoxaparin with tirofiban in patients with UA/NSTEMI not undergoing PCI, compared with UFH and tirofiban. The NICE (National Investigators Collaborating on Enoxaparin) 4 study collected data on the combination of enoxaparin and abciximab in patients undergoing PCI, and both safety and efficacy data compared well with historical data collected on the use of UFH with abciximab. The more recent NICE 3 study extended this finding to the combination of enoxaparin with abciximab, tirofiban or eptifibatide. The safety of two doses of dalteparin and abciximab had also been investigated, with the higher dose the efficacious, and also with safety, in patients undergoing PCI. In addition, a GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes) IV substudy found that dalteparin had equivalent safety to UFH when co-administered with abciximab in patients not undergoing PCI. The NICE 3 and 4 trials were not randomised comparisons, and as such there results must be interpreted with caution. Recently, the CRUISE (Coronary Revascularisation Utilizing Integrelin [eptifibatide] and Single-bolus Enoxaparin) and INTERACT (Integrelin and Enoxaparin randomised assessment of Acute Coronary Syndromes Treatment) studies have provided evidence for both the safety and efficacy of enoxaparin combined with eptifibatide in non-ST elevation patients with acute coronary syndromes. A further study (SYNERGY [Superior Yield of the New strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa inhibitors]) will investigate the efficacy of the combination of enoxaparin with abciximab versus that of UFH and abciximab in a large cohort of 8000 patients.

The use of GP IIb/IIIa agents and LMWH in patients with UA/STEMI has led to their use in those with ST-elevation MI, and studies indicate LMWH is efficacious and can be used safely as an adjunct to thrombolysis. New studies will investigate the use of these agents in patients with STEMI not undergoing thrombolysis and we await the results of these studies.

Notes

Acknowledgements

Dr Cohen has received grant and research support from Aventis, Merck and Guident Corporation. This manuscript was supported by Aventis Pharma.

References

  1. 1.
    Antman EM. Braunwald E. Acute myocardial infarction. In: Braunwald EB, editor. Heart disease: a textbook of cardiovascular medicine. Philadelphia: WB Saunders, 1997: 1116Google Scholar
  2. 2.
    Braunwald E, Mark DB, Cheitlin MD, et al. Unstable angina: diagnosis and management clinical practice guideline no. 10. Rockville (MD): Agency for Health Care Policy and Research and the National Heart Lung and Blood Institute, Public Health Service, US Department of Health and Human Services, 1994, 154Google Scholar
  3. 3.
    Cannon CP. Optimising the treatment of unstable angina. J Thromb Thrombolysis 1995; 2(3): 205–18PubMedGoogle Scholar
  4. 4.
    FRISC study group. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996 Mar 2; 347(9001): 561–8Google Scholar
  5. 5.
    FRAX. I.S. Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAXiparine in Ischaemic Syndrome). Eur Heart J 1999 Nov; 20(21): 1553–62CrossRefGoogle Scholar
  6. 6.
    Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997 Aug 14; 337(7): 447–52Google Scholar
  7. 7.
    Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999 Oct 12; 100(15): 1593–601Google Scholar
  8. 8.
    Fragmin and Fast Revascularisation during Instability in Coronary artery disease Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999 Aug 28; 354(9180): 701–4CrossRefGoogle Scholar
  9. 9.
    Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999 Oct 12; 100(15): 1602–8Google Scholar
  10. 10.
    Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet 2000 Jul 1; 356(9223): 9–16Google Scholar
  11. 11.
    EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Eur Heart J 2001; 22: 554–72Google Scholar
  12. 12.
    Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) [online]. Available from URL: http://www.acc.org/clinical/guidelines/unstable/update/pdf/UA_update.pdf [Accessed 2002 Jul 9]
  13. 13.
    Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000 Sep; 21(17): 1406–32PubMedCrossRefGoogle Scholar
  14. 14.
    Montalescot G, Drouet L. ARMADA study: arandomised comparison of enoxaparin, dalteparin and unfractionated heparin on markers of cell activation in patients with unstable angina [abstract]. Eur Heart J 2001; 22: ii–iv, 663Google Scholar
  15. 15.
    Foster RH, Wiseman LR. Abciximab. An updated review of its use in ischaemic heart disease. Drugs 1998 Oct; 56(4): 629–65Google Scholar
  16. 16.
    McClellan KJ, Goa KL. Tirofiban. A review of its use in acute coronary syndromes. Drugs 1998 Dec; 56(6): 1067–80Google Scholar
  17. 17.
    Goa KL, Noble S. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs 1999 Mar; 57(3): 439–62PubMedCrossRefGoogle Scholar
  18. 18.
    Lewis Jr DH, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983 Aug 18; 309(7): 396–403Google Scholar
  19. 19.
    Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988 Oct 27; 319(17): 1105–11PubMedCrossRefGoogle Scholar
  20. 20.
    Theroux P, Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327(3): 141–5PubMedCrossRefGoogle Scholar
  21. 21.
    Bijsterveld NR, Moons AH, Meijers JC, et al. Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. J Am Coll Cardiol 2002; 39: 811–7Google Scholar
  22. 22.
    Goodman SG, Barr A, Sobtchouk A, et al. Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy. J Am Coll Cardiol 2000; 36: 1507–13PubMedCrossRefGoogle Scholar
  23. 23.
    Fareed J, Hoppensteadt DA, Bick RL. An update on heparins at the beginning of the new millennium. Semin Thromb Hemost 2000; 26 Suppl. 1: 5–21PubMedCrossRefGoogle Scholar
  24. 24.
    Montalescot G, Collet JP, Choussat R, et al. A rise of troponin and/or von Willebrand factor over the first 48 h is associated with a poorer 1 -year outcome in unstable angina patients [letter]. Int J Cardiol 2000 Feb 15; 72(3): 293–4PubMedCrossRefGoogle Scholar
  25. 25.
    Montalescot G, Collet JP, Lison L, et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000 Jul; 36(1): 110–4PubMedCrossRefGoogle Scholar
  26. 26.
    Antman EM, Cohen M, McCabe C, et al. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. Eur Heart J 2002; 23: 308–14PubMedCrossRefGoogle Scholar
  27. 27.
    Cohen M. Low molecular weight heparins in the management of unstable angina/non-Q-wave myocardial infarction. Semin Thromb Hemost 1999; 25 Suppl. 3: 113–21PubMedGoogle Scholar
  28. 28.
    Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000 Jun 3; 355(9219): 1936–42PubMedCrossRefGoogle Scholar
  29. 29.
    Fox KAA, Antman E, Cohen M, et al. on behalf of the ESSENCE/TIMI 11B Investigators. Are treatment effects of enoxaparin (low-molecular-weight heparin) more marked in those undergoing percutaneous intervention (PCI): results of ESSENCE/TIMI 11B [abstract]. Eur Heart J 2000; 21: 599Google Scholar
  30. 30.
    Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001 Feb 6; 103(5): 658–63PubMedCrossRefGoogle Scholar
  31. 31.
    Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001 Apr; 13(4): 272–8PubMedGoogle Scholar
  32. 32.
    Martin JL, Fry ETA, Serano A, et al. Pharmacokinetic study of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coronary syndromes [abstract]. The PEPCI study. Eur Heart J 2001; 22: 143Google Scholar
  33. 33.
    The Synergy Executive Committee. The SYNERGY trial: study design and rationale. Am Heart J 2002; 143(6): 952–60CrossRefGoogle Scholar
  34. 34.
    Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998 May 21; 338(21): 1498–505CrossRefGoogle Scholar
  35. 35.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998 May 21; 338(21): 1488–97CrossRefGoogle Scholar
  36. 36.
    Roffi M, Chew DP, Mukherjee D, et al. Glycoprotein IIb/IIIa inhibitors in the medical environment of unstable ischemic syndromes without persistent ST segment elevation: a meta analysis of the randomized trials [abstract no. 1253-98]. J Am Coll Cardiol 2001; 37 (2 Suppl. A): 365AGoogle Scholar
  37. 37.
    PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998 Aug 13; 339(7): 436–43Google Scholar
  38. 38.
    Newby LK, Ohman EM, Christenson RH, et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: thePARAGON-B troponin T substudy. Circulation 2001 Jun 19; 103(24): 2891–6PubMedCrossRefGoogle Scholar
  39. 39.
    Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001 Jun 16; 357(9272): 1915–24PubMedCrossRefGoogle Scholar
  40. 40.
    Thel MC, Califf RM, Tcheng JE, et al. Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. Am Heart J 1999; 137: 264–73CrossRefGoogle Scholar
  41. 41.
    Lincoff AM, Mark DB, Tcheng JE, et al. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation 2000 Dec 12; 102(24): 2923–9Google Scholar
  42. 42.
    Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999 May 27; 340(21): 1623–9PubMedCrossRefGoogle Scholar
  43. 43.
    O’Shea JC, Hafley GE, Greenberg S, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA 2001 May 16; 285(19): 2468–73PubMedCrossRefGoogle Scholar
  44. 44.
    The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998 Jul 11; 352(9122): 87–92Google Scholar
  45. 45.
    Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957–66PubMedCrossRefGoogle Scholar
  46. 46.
    Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895–903PubMedCrossRefGoogle Scholar
  47. 47.
    Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998 Aug 25; 98(8): 734–41Google Scholar
  48. 48.
    Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103: 2572–8PubMedCrossRefGoogle Scholar
  49. 49.
    Topol EJ, Moliterno DJ, Herrmann HC, et al., for the TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001 Jun 21; 344(25): 1888–94PubMedCrossRefGoogle Scholar
  50. 50.
    Boden WE, O’Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998; 338: 1785–92Google Scholar
  51. 51.
    Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344(25): 1879–87PubMedCrossRefGoogle Scholar
  52. 52.
    The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997 Sep 2; 96(5): 1445–53Google Scholar
  53. 53.
    Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomised, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. IMPACT Investigators. Circulation 1995 Apr 15; 91(8): 2151–7Google Scholar
  54. 54.
    James S, Pfisterer M, Husted S, et al. Safety and efficacy of abciximab in addition to the LMW heparin dalteparin as the primary treatment of Acute Coronary Syndromes (ACS) [abstract]. J Am Coll Cardiol 2001; 37 (2 Suppl.): A1150–83Google Scholar
  55. 55.
    Cohen M, Theroux P, Weber S, et al. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999; 71: 273–81PubMedCrossRefGoogle Scholar
  56. 56.
    Cohen M, Théroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in tirofiban and aspirin treated patients with non-st segment elevation acute coronary syndromes: the ACUTE II study. Am Heart J 2002. In pressGoogle Scholar
  57. 57.
    Ferguson JJ, Antman EM, Bates ER, et al. The use of enoxaparin and IIb /IIIa antagonists in acute coronary syndromes, including PCI: final results of the NICE-3 study [abstract no. 1253-97]. J Am Coll Cardiol 2001; 37 (2 Suppl. A): 365AGoogle Scholar
  58. 58.
    Kereiakes DJ, Kleiman NS, Fry E, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001 Mar; 141(3): 348–52PubMedCrossRefGoogle Scholar
  59. 59.
    Bhatt DL, Lincoff AM, on behalf of the CRUISE investigators. Combined use of Eptifibatide and enoxaparin in patients undergoing Percutaneous Coronary Interventions: The Results of the CRUISE trial. 74th Annual meeting of the American Heart Association; 2001 Nov 11–14; Anaheim (CA)Google Scholar
  60. 60.
    Goodman SG. The Intergrilin and Enoxaparin randomized assessment of Acute Coronary Syndromes Treatment (INTERACT). 51st annual session of the American College of Cardiology; 2002 Mar 17–20; Atlanta (GA)Google Scholar
  61. 61.
    Berkowitz SD, Stinnett S, Cohen M, et al. Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. Am J Cardiol 2001; 88(11): 1230–4PubMedCrossRefGoogle Scholar
  62. 62.
    Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001 Aug 25; 358(9282): 605–13PubMedCrossRefGoogle Scholar
  63. 63.
    Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 trial. Circulation 2002; 105(14): 1642–9PubMedCrossRefGoogle Scholar
  64. 64.
    Cohen M, Maritz F, Gensini GF, et al. The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design. J Thromb Thrombolysis 2000; 10(3): 241–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Division of CardiologyMCP-Hahnemann School of MedicinePhiladelphiaUSA

Personalised recommendations